University of North Carolina at Chapel Hill (US)
Access 250+ million papers and cite this researcher's work with AI assistance
H-index
106
Publications
1852
Citations
56465
i10-index
528
Want to find and read papers by this researcher? AnswerThis gives you instant access.
Sign Up Free| Title | Year | Citations |
|---|---|---|
Regorafenib monotherapy for previously treated met... | 2012 | 2840 |
Nivolumab in patients with metastatic DNA mismatch... | 2017 | 2747 |
Durable Clinical Benefit With Nivolumab Plus Ipili... | 2018 | 2014 |
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activa... | 2017 | 1554 |
Randomized Trial of TAS-102 for Refractory Metasta... | 2015 | 1391 |
Colorectal cancer | 2010 | 1349 |
EPIC: Phase III Trial of Cetuximab Plus Irinotecan... | 2008 | 947 |
Effect of First-Line Chemotherapy Combined With Ce... | 2017 | 865 |
Prognostic and predictive value of primary tumour ... | 2017 | 817 |
Fluorouracil, Leucovorin, and Irinotecan Plus Cetu... | 2015 | 790 |
Heinz‐Josef Lenz is a researcher with 1852 publications and 56465 citations. They are affiliated with University of North Carolina at Chapel Hill. Their research focuses on . With an h-index of 106, they are among the top researchers in their field.
Distribution of citations across publications
AnswerThis uses AI to help you search, understand, and cite research from Heinz‐Josef Lenz and 250M+ other papers.
Citations per publication by year